Lutikizumab

Healio Dermatology compiles top hidradenitis suppurativa articles of 2024, highlighting new FDA-approved treatments and conference content.

The hidradenitis suppurativa market is projected to grow at a CAGR of 12.4% by 2034, driven by increased awareness, treatment access, biologic therapy approvals, and a robust pipeline. The market size in the 7MM was USD 1.4 billion in 2023, with approximately 6.2 million prevalent cases. Key companies and treatments include Incyte Corporation, AbbVie, MoonLake Immunotherapeutics, and therapies like Povorcitinib, RINVOQ, Lutikizumab, and Sonelokimab. Regulatory milestones and clinical trials are advancing, with potential market shifts expected from emerging therapies.

Hidradenitis suppurativa (HS) treatment insights highlight B cells, fibroblasts, and bacterial triggers as central to inflammation and fibrosis, with recent trials showing varying success rates for therapies targeting these elements, necessitating further research to understand HS pathogenesis and optimize treatment responses.